Neupulse secures £2.5m in seed funding led by Eos Advisory to advance its wearable anti-tic device towards commercialisation.
The seed round was led by Eos Advisory with US investor backing to support regulatory approval across international markets.
University of Nottingham spinout developing a wearable device to manage the symptoms of Tourette syndrome through nerve stimulation.
Neupulse has secured £2.5m in a seed funding round led by Eos Advisory, with participation from a consortium of US investors. The capital will support the company as it advances towards the regulatory approval phase in the UK, Europe, and the USA for its wearable anti-tic device.
The Nottingham-based firm has finalized a working prototype that stimulates the median nerve in the wrist. Clinical trials conducted in 2023 demonstrated that the technology can reduce tics by over 25 percentile, offering an alternative to traditional pharmacological treatments and cognitive behavior therapy for Tourettes Syndrome.